In children, idiopathic nephrotic syndrome (NS) generally responds well to treatment with corticosteroids, but long-term use of steroids in children can produce adverse effects (AEs) such as growth impairment and hypertension. Calcineurin inhibitors, too, are associated with AEs, including toxicity and diabetes. Rituximab has been proposed as an option for difficult-to-treat childhood-onset NS, and a recent study evaluated the efficacy and safety of a single dose of rituximab in this setting.
In children, idiopathic nephrotic syndrome (NS) generally responds well to treatment with corticosteroids, but long-term use of steroids in children can produce adverse effects (AEs) such as growth impairment and hypertension. Calcineurin inhibitors, too, are associated with AEs, including toxicity and diabetes. Rituximab has been proposed as an option for difficult-to-treat childhood-onset NS, and a recent study evaluated the efficacy and safety of a single dose of rituximab in this setting.
The study, a multicenter, open-label trial conducted in Korean patients with childhood-onset NS, involved patients aged under 24 years who were either drug-dependent for more than 2 years or who were intolerant to standard treatment.
The study’s design involved a randomized controlled trial (RCT) for drug-dependent patients and a single-arm study for patients whose disease was resistant to conventional treatment. In the RCT, patients were randomly assigned to receive either rituximab (n = 40) or standard treatment (n = 21), and in the single-arm study, all patients (n = 23) received rituximab in addition to their pre-enrollment treatment.
The primary end points of the study were the rate of retaining remission at 6 months in the RCT and the rate of remission within 6 months of starting rituximab in the single-arm study.
In the RCT, at 6 months, 74.3% of rituximab-treated patients were at remission, while 68.7% of standard therapy patients in the control group were in relapse (P = .003). The median duration of remission in the rituximab group was 9 months versus 2.9 months in the standard therapy group.
In the single-arm study, within 6 months of starting rituximab, 9 patients achieved either partial (n = 2) or complete (n = 7) remission.
In all patients treated with rituximab, CD19-positive B cells were depleted within 2 weeks of rituximab treatment. However, relapse after rituximab was not always linked with B-cell recovery; 4 patients had depleted B cells at the time of NS relapse.
In total, 50.8% of patients had infusion reactions to rituximab, and 5 of these patients discontinued infusion (all 5 patients were able to tolerate subsequent rituximab administrations, however). A total of 21 patients reported infections, and 45 experienced any AE. One patient died during the study, but the death was not attributable to rituximab therapy, the investigators concluded.
“Our study laid one more piece of evidence that [rituximab] can be safe and effective in patients with childhood-onset, medication-dependent NS,” wrote the authors, adding that controlled studies are warranted to determine the optimal dosing and interval for rituximab administration in patients with hard-to-treat NS.
Reference
Anh YH, Kim SH, Han KH, et al. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea. Medicine (Baltimore). 2018;97:e13158. doi: 10.1097/MD.0000000000013157.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.